Alpha Tau Medical (DRTS) EBIT (2021 - 2026)

Alpha Tau Medical (DRTS) has 6 years of EBIT data on file, last reported at $13.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 43.03% year-over-year to $13.3 million; the trailing twelve-month figure through Mar 2026 stood at $46.3 million (up 25.37% YoY), and the FY2025 full-year result was $42.3 million, up 17.33% from the prior year.
• EBIT climbed to $13.3 million in Q1 2026, from $12.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $13.3 million in Q1 2026 to a low of $7.4 million in Q3 2022.
• A 5-year average of $9.4 million and a median of $8.9 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT surged 221.06% in 2022 and fell 7.11% in 2024, its largest moves.
• Tracing DRTS's EBIT over 5 years: stood at $8.0 million in 2022, then gained by 24.52% to $9.9 million in 2023, then increased by 3.33% to $10.3 million in 2024, then advanced by 22.66% to $12.6 million in 2025, then rose by 5.64% to $13.3 million in 2026.
• Business Quant data shows DRTS's EBIT at $13.3 million in Q1 2026, $12.6 million in Q4 2025, and $10.7 million in Q3 2025.